{"name":"Lupin Ltd.","slug":"lupin-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2006-01-01","label":"Brovana first approved","drug":"Brovana","drugSlug":"arformoterol","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-11-28","label":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE Phase 2 readout (Type 2 Diabetes)","drug":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE","drugSlug":"dapagliflozin-saxagliptin-monohydrate","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"ARMLUPEG","genericName":"PEGFILGRASTIM-UNNE","slug":"pegfilgrastim-unne","indication":"Other","status":"marketed"},{"name":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE","genericName":"DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE","slug":"dapagliflozin-saxagliptin-monohydrate","indication":"Other","status":"marketed"},{"name":"Lupin albuterol HFA MDI","genericName":"Lupin albuterol HFA MDI","slug":"lupin-albuterol-hfa-mdi","indication":"Other","status":"phase_3"},{"name":"Lupin's Pegfilgrastim","genericName":"Lupin's Pegfilgrastim","slug":"lupin-s-pegfilgrastim","indication":"Other","status":"marketed"},{"name":"Oral Capsule Mexiletine (IR)","genericName":"Oral Capsule Mexiletine (IR)","slug":"oral-capsule-mexiletine-ir","indication":"Ventricular arrhythmias","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Brovana","genericName":"ARFORMOTEROL","slug":"arformoterol","indication":"Chronic bronchitis","status":"marketed"},{"name":"Reference Product (Spiriva®)","genericName":"Reference Product (Spiriva®)","slug":"reference-product-spiriva","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"}]}],"pipeline":[{"name":"Brovana","genericName":"ARFORMOTEROL","slug":"arformoterol","phase":"marketed","mechanism":"Brovana works by activating the beta-2 adrenergic receptor to relax airway muscles and improve breathing.","indications":["Chronic bronchitis","Chronic obstructive lung disease","Pulmonary emphysema"],"catalyst":""},{"name":"ARMLUPEG","genericName":"PEGFILGRASTIM-UNNE","slug":"pegfilgrastim-unne","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE","genericName":"DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE","slug":"dapagliflozin-saxagliptin-monohydrate","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Lupin albuterol HFA MDI","genericName":"Lupin albuterol HFA MDI","slug":"lupin-albuterol-hfa-mdi","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lupin's Pegfilgrastim","genericName":"Lupin's Pegfilgrastim","slug":"lupin-s-pegfilgrastim","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oral Capsule Mexiletine (IR)","genericName":"Oral Capsule Mexiletine (IR)","slug":"oral-capsule-mexiletine-ir","phase":"phase_3","mechanism":"Mexiletine is a class IB antiarrhythmic agent that blocks cardiac sodium channels to suppress abnormal electrical activity and restore normal heart rhythm.","indications":["Ventricular arrhythmias","Suppression of premature ventricular contractions","Long QT syndrome (certain forms)"],"catalyst":""},{"name":"Reference Product (Spiriva®)","genericName":"Reference Product (Spiriva®)","slug":"reference-product-spiriva","phase":"phase_3","mechanism":"Tiotropium is a long-acting anticholinergic (muscarinic antagonist) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment","Asthma (in combination with beta-2 agonists)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"regulatory","source":"Mint","summary":"Lupin shares to be in focus on Thursday as USFDA approves Dapagliflozin and Metformin tablets - Mint","headline":"Lupin shares to be in focus on Thursday as USFDA approves Dapagliflozin and Metformin tablets","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPRUIzb0RGOGh6cDdjSWN2ZXdQYlNKVm02VHBEcm5uWS1GU3YzX2VRYm5TR1pBTUFZd3ZpM2RzRHFGMnM3REltc0s0eXZ6eDZCSkdQWS1NcmFFb29FelVyOVJxQS1MQTV6VDVNRU1uNlV0YXNoWGtaWmJuZTBwU1VUTXBWQWU2dnFwSEZES0dxVDI?oc=5","date":"2026-04-02","type":"pipeline","source":"lupin.com","summary":"PR - Lupin Completes Acquisition of VISUfarma - Lupin | Press Release - lupin.com","headline":"PR - Lupin Completes Acquisition of VISUfarma - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPcFlFbWcxaUo0Q2RZZF9NdExKcUtMbzhyX1M5aVNia0Exb0pwbTVZZDA5VWdoU3dFRk1uSHpSSjN4ZzRJMXg3ZFZFSUxGQmJLd0xxaVJRZXZCZ2F2WHBaa3ltX1o0WHY4ZU9PTFBMaWVRSlBZakd2OURSODV3aXJFcFpxaVFqeFhwcDg2ZlRvcjNHd3llaVJLUUxYa0ltT1o3NWhDLWtKanRGOVRmVVVtSXpsRXpjaW10OWlkSDhLZjBobkxBSkFDeVZ6dlNhLXJ5dldSSWZaanBBaDMyUWow?oc=5","date":"2026-03-06","type":"pipeline","source":"PR Newswire","summary":"Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025 - PR Newswire","headline":"Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOdlgya0ZSc0xIbUxwaW9WRnVfNmxOUno5Z0xfX0llUXJVUFFUM1VBYjMtaWVlbzhLLVdlT0EtUUJDTlFtNjM4Qld1Y0JLTG5vclJFY2dreG1ENUFZM2Frb1VGS1RjQW5kcURDWWh1clpZRnNNZThhM3p1VEFaMHJyT2VfTVZzQ0NXQjdfSHNnTGRvR2xHSHozNWV4MTVkTjQxSU5fd0JBRDRXNlFrWDVIaXN2RmtWUUxJRHJ6bmtiMzI1Njh5T0wzT1ppVzRFNDMtNVpYeXBkTWFBRUhCSXpGU1p5Q21teVZNVE9r?oc=5","date":"2026-02-16","type":"deal","source":"lupin.com","summary":"Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada - Lupin | Press Release - lupin.com","headline":"Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada - Lupin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxORmxlTDl2VW9aenZBRFM2a3Zfdi05aUJ4RXlxY1NVM2dRV3RmS1hjSThEdTdmWGRhZFNveGkzQy1vQS1YcVloSUpCUmJYVTlOOVNGUFNqVTVXbXc3VkdvOGR3US1hOHhLOTdveFlNMm9nbTBUUlJsWGI0U040QmRJZXNueVhjVlo0eUxwclFIQWxiZDEydDJFTGctanM5QVExOFFoc2N4TXlubEpiLURaOEJCU2lURVlyWHBxa3ozRmhLelVTXzVDbTVSdDVEQmxRb2ZXMUN4Y2pRa2JuQWFOUGVBcjBGUVU?oc=5","date":"2026-02-10","type":"patent","source":"Reuters","summary":"India's Lupin settles US patent dispute with Astellas Pharma for $90 million - Reuters","headline":"India's Lupin settles US patent dispute with Astellas Pharma for $90 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPSXZlNkVOV2Zja3hqbmxhclhOVEdtcWZhRjVneHhGZlRCN21rZ2plUV8tMXNfVWVVQVR6c2o0ZnoyU1hwRmR5ZlRrcVpuLUt3c1VON3gyUzJndTB3cWlhQi1kSFV0eWMyV1NBc0haMzdDb3RRbzVYVnFIRVlIR1Z6d0lJajlqdmdrdk9XQXBET29tVVlFNXVlUVpvekdtMHd3Z1BN?oc=5","date":"2026-02-08","type":"pipeline","source":"lupin.com","summary":"Lupin completes acquistion of pharma dynamics, South Africa - Lupin | Press Release - lupin.com","headline":"Lupin completes acquistion of pharma dynamics, South Africa - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOQXdKWUhFRE56MTYxX29xeGFDQVRPMGFXSmV1SS1uUDhLSWV2V1BPTjlDdTRoX2VGclhoTEdiVEltUTVKLVhyWkJiU2dGQXFCdkNoQ3lQOC1oRFJOV2VWRmxrZ2VzaVdacDNERDJRSDYxbTFaZWE0eUVlVEQyQmhtYUs3LUxOZTZjMmJiV3V6TXFrNTdobUVOYjRsMG05Z2JVaW10b1MxNA?oc=5","date":"2026-02-07","type":"regulatory","source":"lupin.com","summary":"Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA - Lupin | Press Release - lupin.com","headline":"Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ1E5NmV5ZGVqbWVUUXo2bVQ4dlRaZXdlc3IyRHdYRTc3VS1nTllkZktlbnhRVGdTSllUeE5OZk41SzN6clM0ZVdBNmc3MXBwdEZDdktNSEFGRldEVnpYTXc5cmFxaExMX0NuNnpNdkhHSC1sUmJsdl83YVBsdUpxMzlhVzk2T2U0TEZidzh0Mm5oNjFyTFhLRVk1MnIxTjNW?oc=5","date":"2026-02-07","type":"regulatory","source":"lupin.com","summary":"Lupin’s Pithampur Unit-3 (Indore) receives EIR from U.S. FDA - Lupin | Press Release - lupin.com","headline":"Lupin’s Pithampur Unit-3 (Indore) receives EIR from U.S. FDA - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPZ1ZJQ0hwczh5NUZ1OWRKMDdZQUdhQXBfOFZTaEhUTzR5dW5UZms3Y3lIZGlpVWVSNFRhYjNTakdkM3NuanduUUd0bFp2ZjZlbXVfdTFoU3U0c29mM2tOX09xOFBpcWhFN3JaV2FObmtWc0tUb090bUxWcmVELTlianZoT2huT05mMkE?oc=5","date":"2026-02-07","type":"patent","source":"lupin.com","summary":"Lupin Launches Generic PhosLo® in the US - Lupin | Press Release - lupin.com","headline":"Lupin Launches Generic PhosLo® in the US - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQWnVmUGNqbjZhTkx4QlRiZDF6dzVENmpUMUJpTHpmbGoybk5MV05tMWJpV213RmkyWFpDWHEzd0lqNHhYNGJES25oRWs1cTZCb3N5NUVsOVJHT1JRUmVGREFVQ0pJV3hFWTNydDBtLUp1RU1qSjVsVVFlVjZ2U05FbnRHN1d4dEFxU0tNYjRkOEFLMkpOSjFrdXo4UEdXa2k1bXdsMHdGR1pPMUNSRnBFY2tn?oc=5","date":"2025-10-29","type":"pipeline","source":"New Jersey Business Magazine","summary":"Pharma Firm Lupin Limited Inaugurates New Corporate Offices in Bridgewater - New Jersey Business Magazine","headline":"Pharma Firm Lupin Limited Inaugurates New Corporate Offices in Bridgewater","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOZEU0SVJ4NnRsS21aQkJnUjBmbk8tb3VIV0xZMmtTZVJBa3JsQThVN2ZOSDVSbUlNT2pzUmVpazlTbl80LW1sbkNpMi1tSEpJZWFycXM2RkJXZDkyc2V6WWppNHZWVjhaWlhoc2xKOWtiYVpuTWthV2g0SWZsMUpNQkxGZVNZX192SzFYZXZ2dlNUSnBDc3RJbEFfX2Ruam8?oc=5","date":"2025-10-28","type":"earnings","source":"Contract Pharma","summary":"Lupin Inaugurates New Headquarters in Bridgewater, NJ - Contract Pharma","headline":"Lupin Inaugurates New Headquarters in Bridgewater, NJ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPSGlEbnZOdURwb2hhT3NxYktySEc4cThyeU1HYnRYVzBUUlpkcndQN0xIbUVtYjgxcEJOOEROaFRaaXlLREI5enpsSF81Q0hBSE5XU0tsSElSVFpoTEdLOTZJc0RBaWFYUVRvOXVld0p3QXUwRXFra1dQS19IWW84djI3MUJvZ2s2NEtLdkMybWlURnY0VEJPU293Z3F2ZUNZb2tPT0RhalNBRE1xaDl0ZDIwSnYwaHE1TFRiQTNKYw?oc=5","date":"2025-10-09","type":"pipeline","source":"Fierce Pharma","summary":"Lupin rides the onshoring wave, pledging $250M to build new respiratory production plant in Fla. - Fierce Pharma","headline":"Lupin rides the onshoring wave, pledging $250M to build new respiratory production plant in Fla.","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":4,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}